Author:
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 423 | 176 | 13 |
| Full Text Views | 13 | 0 | 0 |
| PDF Downloads | 10 | 0 | 0 |
Short-Course Norfloxacin and Trimethoprim-Sulfamethoxazole Treatment of Shigellosis and Salmonellosis in Egypt
Samir Bassily
Samir Bassily
U.S. Naval Medical Research Unit No. 3, Infectious Disease Department and Enterics Division, U.S. Naval Medical Research Institute, Abbassia Fever Hospital, Egyptian Ministry of Health, Cairo, Egypt
Search for other papers by Samir Bassily in
Current site
Google Scholar
PubMed
Search for other papers by Samir Bassily in
Current site
Google Scholar
PubMed
Kenneth C. Hyams
Kenneth C. Hyams
U.S. Naval Medical Research Unit No. 3, Infectious Disease Department and Enterics Division, U.S. Naval Medical Research Institute, Abbassia Fever Hospital, Egyptian Ministry of Health, Cairo, Egypt
Search for other papers by Kenneth C. Hyams in
Current site
Google Scholar
PubMed
Search for other papers by Kenneth C. Hyams in
Current site
Google Scholar
PubMed
Nabil A. El-Masry
Nabil A. El-Masry
U.S. Naval Medical Research Unit No. 3, Infectious Disease Department and Enterics Division, U.S. Naval Medical Research Institute, Abbassia Fever Hospital, Egyptian Ministry of Health, Cairo, Egypt
Search for other papers by Nabil A. El-Masry in
Current site
Google Scholar
PubMed
Search for other papers by Nabil A. El-Masry in
Current site
Google Scholar
PubMed
Zoheir Farid
Zoheir Farid
U.S. Naval Medical Research Unit No. 3, Infectious Disease Department and Enterics Division, U.S. Naval Medical Research Institute, Abbassia Fever Hospital, Egyptian Ministry of Health, Cairo, Egypt
Search for other papers by Zoheir Farid in
Current site
Google Scholar
PubMed
Search for other papers by Zoheir Farid in
Current site
Google Scholar
PubMed
Eleanor Cross
Eleanor Cross
U.S. Naval Medical Research Unit No. 3, Infectious Disease Department and Enterics Division, U.S. Naval Medical Research Institute, Abbassia Fever Hospital, Egyptian Ministry of Health, Cairo, Egypt
Search for other papers by Eleanor Cross in
Current site
Google Scholar
PubMed
Search for other papers by Eleanor Cross in
Current site
Google Scholar
PubMed
August L. Bourgeois
August L. Bourgeois
U.S. Naval Medical Research Unit No. 3, Infectious Disease Department and Enterics Division, U.S. Naval Medical Research Institute, Abbassia Fever Hospital, Egyptian Ministry of Health, Cairo, Egypt
Search for other papers by August L. Bourgeois in
Current site
Google Scholar
PubMed
Search for other papers by August L. Bourgeois in
Current site
Google Scholar
PubMed
Ezzat Ayad
Ezzat Ayad
U.S. Naval Medical Research Unit No. 3, Infectious Disease Department and Enterics Division, U.S. Naval Medical Research Institute, Abbassia Fever Hospital, Egyptian Ministry of Health, Cairo, Egypt
Search for other papers by Ezzat Ayad in
Current site
Google Scholar
PubMed
Search for other papers by Ezzat Ayad in
Current site
Google Scholar
PubMed
Richard G. Hibbs
Richard G. Hibbs
U.S. Naval Medical Research Unit No. 3, Infectious Disease Department and Enterics Division, U.S. Naval Medical Research Institute, Abbassia Fever Hospital, Egyptian Ministry of Health, Cairo, Egypt
Search for other papers by Richard G. Hibbs in
Current site
Google Scholar
PubMed
Search for other papers by Richard G. Hibbs in
Current site
Google Scholar
PubMed
In a double-blind clinical study, 109 adult Egyptian patients infected with Shigella spp. and 45 infected with Salmonella spp. were randomly assigned to three treatment groups: 1) norfloxacin in a single 800-mg dose, 2) norfloxacin, 400 mg twice a day for three days, and 3) trimethoprim (160 mg)-sulfamethoxazole (800 mg) (TMP-SMX), twice a day for three days. Among Shigella-infected patients, diarrheal symptoms had resolved in 86–97% and bacteriologic failure (repeat positive stool culture) occurred in only two patients five days after the start of the three treatment regimens. Among Salmonella-infected patients, diarrheal symptoms had resolved in 76–82% of patients and bacteriologic failure was common (18–36%) five days after the start of therapy. These data indicate that short-course therapy with either norfloxacin or TMP-SMX can be effectively used to treat shigellosis in adults in developing countries. However, for uncomplicated Salmonella spp. infection, short-course therapy with norfloxacin and TMP-SMX may not lead to a rapid resolution of symptoms or consistently eliminate this enteropathogen.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 423 | 176 | 13 |
| Full Text Views | 13 | 0 | 0 |
| PDF Downloads | 10 | 0 | 0 |